Kiribati vs South-East Asia (WHO region): Treatment success rate for patients treated for MDR-TB
Kiribati
100.0%
in 2022
South-East Asia (WHO region)
77.0%
in 2022
Kiribati rank
1st
South-East Asia (WHO region) rank
2nd
Treatment success rate for patients treated for MDR-TB over time
- Kiribati
- South-East Asia (WHO region)
How they compare
Kiribati currently reports 100.0% against 77.0% in South-East Asia (WHO region), a difference of 23.0%.
That makes Kiribati's figure about 1.3 times South-East Asia (WHO region)'s.
Across all 6 years both countries report, Kiribati has been ahead every year.
Kiribati ranks 1st and South-East Asia (WHO region) ranks 2nd of 163 countries.
Kiribati has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kiribati | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100.0% | 55.0% | 45.0% | Kiribati |
| 2020s | 91.5% | 73.0% | 18.5% | Kiribati |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Kiribati or South-East Asia (WHO region)?
- Kiribati, at 100.0% against 77.0% in South-East Asia (WHO region) as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Kiribati and South-East Asia (WHO region)?
- 23.0%, with Kiribati ahead.
- How many years of comparable data are there for Kiribati and South-East Asia (WHO region)?
- 6 years are reported by both, from 2015 to 2022.
- How do Kiribati and South-East Asia (WHO region) rank globally for treatment success rate for patients treated for mdr-tb?
- Kiribati ranks 1st and South-East Asia (WHO region) ranks 2nd of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.